A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus
Sanjay Kalra, Rakesh Sahay
Abstract
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a well-established class of glucose-lowering drugs. GLP-1 RAs can be classified according to their structure, duration of action and mode of administration. This review describes the basic and clinical pharmacology of orally administered semaglutide. It highlights the PIONEER clinical trial programme results, and reviews the efficacy, safety and tolerability.
Topics & Concepts
SemaglutideMedicineTolerabilityGlucagon-like peptide 1 receptorType 2 Diabetes MellitusAgonistDiabetes mellitusType 2 diabetesPharmacologyGlucagon-like peptide-1ReceptorGlucagonInternal medicineEndocrinologyInsulinAdverse effectLiraglutideDiabetes Treatment and ManagementPancreatic function and diabetesMetabolism, Diabetes, and Cancer